Management of Primary Refractory Diffuse Large B-Cell Lymphoma in Patients Unsuitable for CAR T-Cell Therapy - PubMed
4 days ago
- #CAR T-cell therapy
- #bispecific antibodies
- #DLBCL
- Primary refractory Diffuse Large B-Cell Lymphoma (DLBCL) has poor outcomes and limited response to conventional salvage therapies.
- CAR T-cell therapy is the standard of care, but many patients are unsuitable due to reversible clinical conditions, rapid disease progression, or logistical barriers.
- Alternative strategies include platinum-based or gemcitabine- and bendamustine-containing regimens for short-term disease control.
- Novel antibody-based therapies like polatuzumab combinations, loncastuximab tesirine, and tafasitamab plus lenalidomide offer improved tolerability.
- CD20 × CD3 bispecific antibodies provide off-the-shelf immune engagement and can be administered outpatient.
- Early identification of reversible barriers to CAR T-cell therapy and timely use of bispecific antibodies are critical for disease control and restoring eligibility for cellular therapy.